Clinical Trial Update: Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating cisplatin, pemetrexed, and bevacizumab for untreated malignant mesothelioma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma

Drugs mentioned

• Bevacizumab (bevacizumab)
• CISPLATIN (cisplatin)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Mesothelioma | Phase 2 | Status: COMPLETED | Results posted: 2017-01-05